1. 1. Radmard AR. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143.
2. 2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
3. 3. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91-5.
4. 4. Zhang R, Su B. Small but influential: the role of microRNAs on gene regulatory network and 3′ UTR evolution. JGG. 2009;36(1):1-6.
5. 5. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350.
6. 6. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Bba-Mol Cell Res. 2010;1803(11):1231-43.
7. 7. Wang A-M, Huang T-T, Hsu K-W, Huang K-H, Fang W-L, Yang M-H, et al. Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget. 2014;5(13):5002.
8. 8. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193.
9. 9. Bader AG. miR-34–a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3.
10. 10. Tahergorabi Z, Moodi M, Mesbahzadeh B. Breast Cancer: A preventable disease. j birjand univ med sci. 2014;21(2):126-41.
11. 11. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328-37.
12. 12. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479-85.
13. 13. Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, González-Fernández Á. Assessment of the Evolution of Cancer Treatment Therapies. Cancers (Basel). 2011;3(3): 3279–3330.
14. 14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
15. 15. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer lett. 2009;285(2):116-26.
16. 16. Ha M, Kim VN. Regulation of microRNA biogenesis. Nature reviews Molecular cell biology. 2014;15(8):509-24.
17. 17. Khoshmirsafa M, Seif F, Mohsenzadegan M, Najafi M, Mokhtarian K, Shekarabi M. Circulating microRNAs, valuable biomarkers in biological fluids. RJMS. 2017;24(160):22-36.
18. 18. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell cycle. 2008;7(6):759-64.
19. 19. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010;29(11):1580.
20. 20. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008;68(1):26-33.
21. 21. McInroy L, Määttä A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun. 2007;360(1):109-14.
22. 22. Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30(11):1903-9.
23. 23. Gao H, Zhao H, Xiang W. Expression level of human miR-34a correlates with glioma grade and prognosis. J Neurooncol. 2013;113(2):221-8.
24. 24. Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao H, et al. miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells. Tumour Biol. 2014;35(2):1503-10.
25. 25. Zhang H, Li S, Yang J, Liu S, Gong X, Yu X. The prognostic value of miR-34a expression in completely resected gastric cancer: tumor recurrence and overall survival. Int J Clin Exp Med.
26. 2015;8(2):2635.
27. 26. Lin X, Xu X, Chen Q, Huang C. Clinical significance of microRNA-34a in esophageal squamous cell carcinoma. Genet Mol Res. 2015;14:17684-91.
28. 27. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011;10(8):1470-80.
29. 28. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-46.
30. 29. Ngan C, Yamamoto H, Seshimo I, Tsujino T, Man-i M, Ikeda J, et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer. 2007;96(6):986-92.